Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) EBIT: 2019-2025

Historic EBIT for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$34.4 million.

  • C4 Therapeutics' EBIT fell 21.84% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of -$119.6 million for FY2024, which is 13.97% up from last year.
  • C4 Therapeutics' EBIT amounted to -$34.4 million in Q3 2025, which was down 20.74% from -$28.5 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EBIT ranged from a high of -$15.3 million in Q4 2021 and a low of -$38.3 million during Q4 2022.
  • Over the past 3 years, C4 Therapeutics' median EBIT value was -$32.2 million (recorded in 2024), while the average stood at -$31.9 million.
  • As far as peak fluctuations go, C4 Therapeutics' EBIT crashed by 151.02% in 2022, and later skyrocketed by 42.92% in 2024.
  • Over the past 5 years, C4 Therapeutics' EBIT (Quarterly) stood at -$15.3 million in 2021, then tumbled by 151.02% to -$38.3 million in 2022, then increased by 2.26% to -$37.4 million in 2023, then declined by 0.75% to -$37.7 million in 2024, then fell by 21.84% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q3 2025, -$28.5 million for Q2 2025, and -$29.2 million during Q1 2025.